5th International Workshop on Adverse Drug Reactions and Lipodystrophy, 8-11 July 2003, Paris
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Lipodystrophy Workshop (IWADRW) 5th Paris 2003
Underlying mechanisms: adipocytes and cytokines
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications, Basic science and immunology.
More mitochondrial DNA depletion
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
IMT and cardiovascular risk
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Reduced bone mineral density in HIV-positive women
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Rosiglitazone with insulin resistance
1 September 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Additional benefits of exercise with metformin
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Mitochondrial toxicity with AZT and d4T – and benefits of switch to abacavir
1 September 2003. Related: Conference reports, Antiretrovirals, Lipodystrophy and metabolic complications.
Facial fat loss – measuring and treatment
1 September 2003. Related: Conference reports, Treatment access, Lipodystrophy and metabolic complications.
Uridine treatment for mitochondrial toxicity
1 September 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Breast enlargement in men and testosterone treatment
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Severe efavirenz psychotic events
1 September 2003. Related: Conference reports, Side effects.
Treatment interruption: a real choice
1 September 2003. Related: Conference reports, Treatment strategies, Lipodystrophy and metabolic complications.
Uridine as a potential treatment for NRTI related mitochondrial toxicity
1 September 2003. Related: Conference reports, PK and drug interactions, Side effects.